Get started
Author

Irina Surovtsova

Observed names: I Surovtsova, I. Surovtsova
ORCID: 0009-0003-4263-6250
Observed ORCID: 0009-0003-4263-6250
OpenAlex ID: A5048671973
Effects of compliance mismatch on blood flow in an artery with endovascular prosthesis
2004 · Irina Surovtsova · Journal of Biomechanics · 31
Accessible methods for the dynamic time-scale decomposition of biochemical systems
2009 · Irina Surovtsova, Natalia Simus, et al. · Bioinformatics · 30
PDF
SYCAMORE—a systems biology computational analysis and modeling research environment
2008 · Andreas Weidemann, Stefan Richter, et al. · Bioinformatics · 30
Simplification of biochemical models: a general approach based on the analysis of the impact of individual species and reactions on the systems dynamics
2012 · Irina Surovtsova, Natalia Simus, et al. · BMC Systems Biology · 23
PDF
Oncologic Outcomes for Different Axillary Staging Techniques in Patients with Nodal-Positive Breast Cancer Undergoing Neoadjuvant Systematic Treatment: A Cancer Registry Study
2024 · André Pfob, Daria B. Kokh, et al. · Annals of Surgical Oncology · 10
Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort
2023 · Andreas Teufel, Isaac Rodriguez, et al. · Journal of Gastrointestinal and Liver Diseases · 9
PDF
Ca2+ dynamics correlates with phenotype and function in primary human neutrophils
2013 · Katrin Hübner, Irina Surovtsova, et al. · Biophysical Chemistry · 9
Approaches to Complexity Reduction in a Systems Biology Research Environment (SYCAMORE)
2006 · Irina Surovtsova, Sven Sahle, et al. · Winter Simulation Conference · 7
Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
2025 · Irina Surovtsova, Felix J. F. Herth, et al. · Pulmonology · 6
PDF
Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry
2024 · Jasmin Schuhbaur, Irina Surovtsova, et al. · BMC Cancer · 3
PDF
Use of chemotherapy and loco‐regional therapy in stage IA triple‐negative breast cancer and their association with oncologic outcomes: A cancer registry study
2024 · André Pfob, Irina Surovtsova, et al. · International Journal of Cancer · 2
PDF
Inzidenz, Behandlung und Prognose des Prostatakarzinoms in Baden-Württemberg: Analyse anhand von Krebsregisterdaten
2024 · Thomas Stefan Worst, Irina Surovtsova, et al. · Die Urologie · 2
PDF
Sebaceous Carcinoma: A Retrospective Multicenter Analysis of 213 Cases
2026 · Sebastian A. Wohlfeil, Jochen S. Utikal, et al. · Cancers · 1
PDF
Fluid Flows and Free Boundaries
2007 · B. Schweizer, S. Bodea, et al. · Springer eBooks · 1
MO16.03: Sleeve Resection vs Pneumonectomy in NSCLC: Survival Benefit by Age, Nodal Status, and Resection Completeness
2026 · T. Schneider, I. Surovtsova, et al. · Journal of Thoracic Oncology
160P Lymphadenectomy in clinically node-negative ovarian cancer (FIGO I-III): A population-based analysis from the Baden-Wuerttemberg Cancer Registry
2026 · H. Endres, I. Surovtsova, et al. · ESMO Open
PDF
Real-World Emulation of Landmark Lung Cancer Trials: A Registry-Based Reconstruction of KN189, KN407, IMpower133, and PACIFIC
2026 · Irina Surovtsova, Wilfried E. E. Eberhardt, et al. · Cancers
474P Real-world outcomes of first-line endocrine therapy with or without CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: A cancer registry study
2026 · I. Surovtsova, P. Morakis · ESMO Open
312P Real-world treatment landscape of stage III NSCLC: Comparing cisplatin and carboplatin in curative-intent therapy
2026 · W.E.E. Eberhardt, I. Surovtsova, et al. · ESMO Open
PDF
437P Immunotherapy in ES-SCLC: Real-world impact of atezolizumab/durvalumab, radiotherapy, and metastatic burden across ECOG 0-2 patients
2026 · I. Surovtsova, W.E.E. Eberhardt, et al. · ESMO Open
PDF
55P Impact of KRAS/TP53 and KEAP1/STK11 co-mutations on immune checkpoint inhibitor outcomes for metastatic NSCLC patients: Insights from real-world data
2026 · D. Kokh, I. Surovtsova, et al. · ESMO Open
PDF
A0303 Effect of prior nephrectomy and bone metastases on real-world efficacy of ipilimumab/nivolumab and pembrolizumab with TKI in metastatic clear-cell RCC
2026 · I. Surovtsova, P. Morakis · European Urology
Use of bevacizumab for patients with International Federation of Gynecology and Obstetrics stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: a Cancer Registry study
2025 · André Pfob, Irina Surovtsova, et al. · International Journal of Gynecological Cancer
PDF
1886P Metastatic spread and PD-L1 expression co-determine benefit from pembrolizumab in advanced non-squamous NSCLC
2025 · I. Surovtsova, M. Thomas, et al. · Annals of Oncology
852P Evaluating neoadjuvant options in synchronous mCRC RAS mutated or right-sided RAS wild type: A real-world perspective
2025 · I. Surovtsova, T. Seufferlein, et al. · Annals of Oncology
Works count: 49
Citation count: 165
H-index: 7
I10-index: 5
Year
Topic
Type